Veru Inc is trading 10.4% down at $3.79 as the stock undergoes consolidation and profit-taking following yesterday's massive 88% rally.
- The prior-day surge was driven by news of a clinical supply agreement with Novo Nordisk for a Phase 2b obesity trial combining enobosarm with Wegovy.
- Today's pre-market pullback appears to be a natural reaction to the sharp move rather than a response to new developments, as no fresh company news has emerged overnight.